Therapy of Hepatitis B;Standardtherapie der chronischen Hepatitis B

Praxis

Volumn 95, Issue 36, 2006, Pages 1383-1388

  Thimme, R ^a   Blum, H E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiviral therapy; Hepatitis B; Interferon

Indexed keywords

EID: 33748792027     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157.95.36.1383     Document Type: Review

References (24)

1. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., Locarnini S.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125: 292-297, 2003. (Pubitemid 36929407)
2. Chisari F.V.: Cytotoxic T cells and viral hepatitis. Journal of Clinical Investigation 99: 1472-1477, 1997.
3. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., Chutaputti A., Chang W.Y., Zahm F.E., Pluck N.: Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepat 10: 298-305, 2003. (Pubitemid 36801917)
4. Craxi A., Di Bona D., Camma C.: Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39: S99-105, 2003.
5. Deres K., Schroder C.H., Paessens A., Goldmann S., Hacker H.J., Weber O., Kramer T., Niewohner U., Pleiss U., Stoltefuss J., Graef E., Koletzki D., Masantschek R.N., Reimann A., Jaeger R., Gross R., Beckermann B., Schlemmer K.H., Haebich D., Rubsamen-Waigmann H.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299: 893-896, 2003. (Pubitemid 36182448)
6. Di Marco V., Lo Iacono O., Camma C., Vaccaro A., Giunta M., Martorana G., Fuschi P., Almasio P.L., Craxi A.: 1999. The long-term course of chronic hepatitis B. Hepatology 30: 257-264, 1999. (Pubitemid 29300594)
7. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., Woessner M., Gardner S., Schiff E.: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37: 748-755, 2003. (Pubitemid 36397384)
8. Ganem D., Prince A.M.: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004. (Pubitemid 38298992)
9. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., Arterburn S., Xiong S., Currie G., Brosgart C.L.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352: 2673-2681, 2005. (Pubitemid 41007822)
10. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., Brosgart C.L.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807, 2003. (Pubitemid 36245756)
11. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., Simon C., So T.M., Gerken G., de Man R.A., Niesters H.G., Zondervan P., Hansen B., Schalm S.W.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123-129, 2005. (Pubitemid 40091801)
12. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., Condreay L.: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 687-696, 2003. (Pubitemid 36337972)
13. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N.A.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129: 528-536, 2005. (Pubitemid 41096641)
14. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., Kleiner D.E., Schmid P., Condreay L.D., Gauthier J., Kuhns M.C., Liang T.J., Hoofnagle J.H.: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32: 828-834, 2000.
15. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., Pluck N.: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695, 2005. (Pubitemid 41007823)
16. Locarnini S.: Molecular virology of hepatitis B virus. Semin Liver Dis 24: 3-10, 2004.
17. Lok A.S., Zoulim F., Locarnini S., Mangia A., Niro G., Decraemer H., Maertens G., Hulstaert F., De Vreese K., Sablon E.: Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 40: 3729-3734, 2002.
18. Manns M.P., Caselmann W.H., Wiedmann K.H., Wedemeyer H.: [Standard treatment of chronic hepatitis B]. Z Gastroenterol 42: 687-691, 2004.
19. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., Lu Z.M., Piratvisuth T., Germanidis G., Yurdaydin C., Diago M., Gurel S., Lai M.Y., Button P., Pluck N.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 : 1206-1217, 2004. (Pubitemid 39296307)
20. Niederau C.: [Criteria for the treatment of chronic hepatitis B and D]. Z Gastroenterol 42: 682-686, 2004.
21. Schiff E.R., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., Tillmann H.L., Samuel D., Zeuzem S., Lilly L., Rendina M., Villeneuve J.P., Lama N., James C., Wulfsohn M.S., Namini H., Westland C., Xiong S., Choy G.S., Van Doren S., Fry J., Brosgart C.L.: Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38: 1419-1427, 2003. (Pubitemid 37466968)
22. van Bommel F., Wunsche T., Mauss S., Reinke P., Bergk A., Schurmann D., Wiedenmann B., Berg T.: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40: 1421-1425, 2004. (Pubitemid 39657017)
23. van Nunen A.B., Hansen B.E., Suh D.J., Lohr H.F., Chemello L., Fontaine H., Heathcote J., Song B.C., Janssen H.L., de Man R.A., Schalm S.W.: Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52: 420-424, 2003. (Pubitemid 36250065)
24. Westland C.E., Yang H., Delaney W.E.T., Gibbs C.S., Miller M.D., Wulfsohn M., Fry J., Brosgart C.L., Xiong S.: Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38: 96-103, 2003. (Pubitemid 36775800)